Steven Kanner PhD

Steve is the Chief Scientific Officer of Caribou Biosciences, responsible for R&D activities related to therapeutic discovery and development. Before joining Caribou, Steve served in positons of increasing responsibility in both oncology and immunology/inflammation drug discovery at Bristol-Myers Squibb, Agensys, and Astex Pharmaceuticals; and was most recently VP, Head of Biology at Arrowhead Pharmaceuticals leading a department in discovery of RNAi therapeutics for oncology, genetic diseases and other indications. Steve has authored over 80 publications in both peer-reviewed journals and books, and is an inventor on multiple patents and patent applications. He earned his undergraduate degree in genetics from the University of California, Berkeley, his PhD in immunology and microbiology from the University of Miami’s Miller School of Medicine, and did post-doctoral work in oncology at the University of Virginia.

Caribou Biosciences, founded in 2011, is a leading company in CRISPR genome engineering. It is focused on the advancement of new applications for CRISPR-Cas gene editing to push forward the development of new medical therapies and bio-based products that offer profound benefits to human health and society. They have developed a CRISPR-Cas technology platform that enables simple, flexible targeting of any site in a genome. Caribou Biosciences applies their technology platform and discoveries in four main markets: therapeutics, agricultural biotechnology, biological research, and industrial biotechnology.